25 Most Attractive Medtech M&A Targets in 2022

In a report published May 20, Mike Matson, a medtech analyst at Needham & Co., called out these 25 public medtech companies as attractive for potential M&A. Matson said he identified companies based on products, growth, and margins. The list does not account for valuations, he cautioned, so some of the companies identified may be too expensive to be acquired based on current valuations.

That said, it does appear to be shifting to more of a buyer's market in medtech, as valuations have dropped significantly. You can read more about the current medtech M&A environment here.